about
Traumatic brain injury as a risk factor for Alzheimer disease. Comparison of two retrospective autopsy cohorts with evaluation of ApoE genotypeParkinsonian syndromesTime to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease.Environmental Exposures and Parkinson's DiseaseThe first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathyAnnonacin in Asimina triloba fruit: implication for neurotoxicityIdentification of common variants influencing risk of the tauopathy progressive supranuclear palsy.Diagnosis and management of dementia with Lewy bodies: third report of the DLB ConsortiumMitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with progressive supranuclear palsy.Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: the GenePD study.Replication of association between ELAVL4 and Parkinson disease: the GenePD study.Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD StudyThe Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study.Phosphorylated α-synuclein in Parkinson's disease.Recent advances in atypical parkinsonian disorders.The RAB39B p.G192R mutation causes X-linked dominant Parkinson's diseaseUpdate of atypical Parkinsonian disorders.Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease.Consensus statement on the diagnosis of multiple system atrophy.Clinical and pathologic presentation in Parkinson's disease by apolipoprotein e4 allele status.Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson diseaseNatural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study.Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options.The FAB: a Frontal Assessment Battery at bedside.Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson's disease.Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trialNeuropsychiatric assessment of Gilles de la Tourette patients: comparative study with other hyperkinetic and hypokinetic movement disorders.Polymorphic genes of detoxification and mitochondrial enzymes and risk for progressive supranuclear palsy: a case control study.Therapy and management of frontal lobe dementia patients.A recommended scale for cognitive screening in clinical trials of Parkinson's disease.MDS clinical diagnostic criteria for Parkinson's disease.MDS research criteria for prodromal Parkinson's disease.Current and future treatments in progressive supranuclear palsy."Applause sign" helps to discriminate PSP from FTD and PD.Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms.Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia.Cognition in movement disorders: where can we hope to be in ten years?Parkinson's disease mild cognitive impairment: application and validation of the criteria.MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI.Cytokine expression and microglial activation in progressive supranuclear palsy.
P50
Q24802281-6DC12B67-BCA7-4537-924C-7F1826F58DDFQ27007524-94393F3B-B7F5-46C0-A9C2-B6CDE38CA276Q27686808-1396112D-FEBA-4E84-B473-7BC22AEFC8B2Q28074723-2B1B9ECD-923F-4694-B426-395E3A9FE94AQ28085165-4044891E-E1C5-4A81-8B32-32BC80FFB766Q28254396-C318D438-9919-48EC-B1D6-1256C3EC5AFDQ29417026-8B69F3B2-9053-419A-8F1D-51A7B68CD4DFQ29614409-A10807C5-021A-44B0-9112-853891FCB237Q30306088-DFC1C3F3-7E18-4A33-9BD6-85817693CE21Q30438950-5B7AB981-A306-4829-999D-D594C935BF6FQ30439050-E5D77EBE-4A21-46D8-B23F-C4E51D6D67D2Q30439341-8A318AD1-B0F6-409A-913A-A3A2A44F3EB9Q30440660-92AEA5EC-08AC-43BC-803E-EBD10770C3FEQ30510167-2041D5D6-0F3F-4820-A4F8-76372D81D374Q30584227-6F159218-E4F4-48F5-B735-04B7043159CBQ30665368-6F13857A-15D3-439D-90AF-EE89BECFA1A2Q31118118-1BCB2A87-36C5-4FBD-A748-395007EDD436Q33589160-4DB802A5-4DD2-4989-92F4-7986042BEB26Q33605440-473FE10B-AECA-4AFF-915E-F47BC7613AEFQ33638836-75E65C19-5E65-4E87-A49C-B8393C54BBC1Q33698810-5E02EF0D-3CFE-40CA-93B8-28441E69C202Q33735302-1F1E844F-138C-499C-9543-5DD15F2469E9Q33761048-3972AC0C-DD77-4C9F-A595-4018ADC36AF5Q33927821-37ECADF5-4E43-4E87-B8E7-0042A33635DEQ33934921-2EAA2FD7-247D-4243-86FC-4C6CEE161E33Q34031302-A7D02D62-2837-4D12-AA65-F6CB38669DB1Q34105520-7234D14B-CE30-41E1-B5EF-F827365DFACDQ34198178-6CAE636D-6A93-48A6-B5BD-2BF8190A1303Q34279232-62E553B8-8BEB-4ACB-B964-22C8B3D1862DQ34300160-B35D3BDF-D35D-4803-84C5-92E6C19241F3Q34498274-515F1F21-5505-4495-B0E7-B1DEC4D9EF5AQ34498279-42117339-9F3D-4B64-A160-D183A8E3A656Q34506364-375826C1-ACED-4280-97E9-B223841DB9C0Q34558906-0BA7DEB5-68B7-49E8-A46E-69FFD2E36FEBQ35012627-10187259-DD54-4EED-AD12-31CC80966503Q35165798-563B7511-CB9B-4C18-B11F-370D90504C18Q35211553-33F35A49-A34F-4650-876A-F0A736DBDE8FQ35233945-198B4602-90F4-4F5C-863F-4B8E0CD874DEQ35234522-96C92966-DA08-43A3-948B-5D7B83E81204Q35388683-2CF98B2E-1D01-4097-BEF3-AC49F593B6FF
P50
subject
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Irene Litvan
@ast
Irene Litvan
@en
Irene Litvan
@es
Irene Litvan
@nl
Irene Litvan
@sl
type
label
Irene Litvan
@ast
Irene Litvan
@en
Irene Litvan
@es
Irene Litvan
@nl
Irene Litvan
@sl
altLabel
I Litvan
@en
Irene Litvan, MD, MSc, FANA
@en
Litvan I
@en
prefLabel
Irene Litvan
@ast
Irene Litvan
@en
Irene Litvan
@es
Irene Litvan
@nl
Irene Litvan
@sl
P1006
P214
P244
P1006
P1053
X-9319-2018
P106
P1153
26642880700
P21
P213
0000 0001 1652 0877
P214
P244
P2798
P31
P4012
P496
0000-0002-3485-3445
P735
P7859
lccn-n93005792